Table 1Selection Criteria

Criteria Description
Population Patients with complete dihydropyrimidine dehydrogenase deficiency or at risk of severe fluoropyrimidine (including 5-FU and capecitabine) toxicity and/or intolerance
Intervention Raltitrexed
Comparator No comparator, 5-FU, capecitabine
Outcomes Q1: Effectiveness (e.g., progression-free survival, overall survival, objective response rate, duration of response, health-related quality of life)

Q2: Safety (e.g., adverse events, serious adverse events, withdrawal due to adverse events, death)

Study designs Health technology assessments, systematic reviews, randomized-controlled trials, non-randomized studies

5-FU = 5-fluorouracil.

From: Raltitrexed in Patients With Dihydropyrimidine Dehydrogenase Deficiency

Cover of Raltitrexed in Patients With Dihydropyrimidine Dehydrogenase Deficiency
Raltitrexed in Patients With Dihydropyrimidine Dehydrogenase Deficiency: Rapid Review [Internet].
Vu T, Spry C; Authors.
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.